Company Encyclopedia
View More
name
Eli Lilly
LLY.US
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache.
4.609 T
LLY.USMarket value -Rank by Market Cap -/-

Financial Score

19/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking1/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE96.82%A
    • Profit Margin30.99%A
    • Gross Margin82.91%A
  • Growth ScoreA
    • Revenue YoY45.41%A
    • Net Profit YoY119.98%A
    • Total Assets YoY52.02%A
    • Net Assets YoY66.55%A
  • Cash ScoreB
    • Cash Flow Margin322.72%C
    • OCF YoY45.41%A
  • Operating ScoreB
    • Turnover0.62B
  • Debt ScoreE
    • Gearing Ratio79.25%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Health Care Up, but Not by Much, as Traders Seek Out Risk -- Health Care Roundup

    Healthcare stocks rose slightly as traders shifted to riskier sectors. Eli Lilly and Novo Nordisk filed for FDA approval of new obesity treatments. Cannabis stocks fell after Trump rescheduled marijuana, affecting recreational sales.

    marketscreener·
    US
    NVO
    -0.33%
    US
    LLY
    +1.45%
    marketscreener·
    US
    NVO
    -0.33%
    US
    LLY
    +1.45%

    Sector Update: Health Care Stocks Rise Late Afternoon

    Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF each adding 0.3%. AbCellera Biologics shares gained 5.2% due to a $36 million settlement. Integer shares climbed 5.6% as Irenic Capital Management built a stake and urged board changes. Eli Lilly shares rose 1.8% after announcing price cuts in Canada. Athira Pharma shares surged 66% after acquiring rights for a breast cancer treatment.

    fidelity·
    US
    ITGR
    +5.92%
    US
    LLY
    +1.45%
    US
    ABCL
    +5.37%
    fidelity·
    US
    ITGR
    +5.92%
    US
    LLY
    +1.45%
    US
    ABCL
    +5.37%

    Best Pharmaceutical Stocks To Add to Your Watchlist - December 18th

    MarketBeat's stock screener tool highlights seven pharmaceutical stocks to watch: Eli Lilly, Insmed, Pfizer, AbbVie, Bristol Myers Squibb, Athira Pharma, and Alnylam Pharmaceuticals. These companies are noted for their high trading volumes and potential for significant gains or losses due to clinical trials, regulatory approvals, and other factors. Investors should monitor these stocks for potential investment opportunities.

    Market Beat·
    US
    LLY
    +1.45%
    US
    ABBV
    -0.66%
    Market Beat·
    US
    LLY
    +1.45%
    US
    ABBV
    -0.66%

    New Obesity Medicine Association Initiative Aims to Scale High-Impact Obesity Healthcare Improvements Nationwide

    The Obesity Medicine Association (OMA) has launched a multi-phase Quality Improvement initiative to enhance obesity care in U.S. outpatient settings. Collaborating with Eli Lilly and Q Synthesis LLC, the program includes a virtual learning collaborative and offers grants up to $150,000 for QI projects. OMA members can participate at no cost, with limited space available.

    Newsfile Corp.·
    US
    LLY
    +1.45%
    Newsfile Corp.·
    US
    LLY
    +1.45%

    Pharmaceutical companies are investing in weight management solutions, with Eli Lilly's oral pill orforglipron showing promising Phase 3 trial results in weight maintenance. Data revealed from ATTAIN-MAINTAIN Phase 3 trial, evaluating orforglipron for weight maintenance over 52 weeks, in individuals who initially received treatment with Novo Nordisk's Wegovy or Zepbound.

    Eli Lilly's oral pill orforglipron shows promising Phase 3 trial results in weight maintenance over 52 weeks, following initial treatment with Novo Nordisk's Wegovy or Zepbound. The ATTAIN-MAINTAIN Phase 3 trial highlights the pharmaceutical industry's focus on long-term sustainability and safety in weight management solutions amid the global obesity epidemic.

    Unusual Whales·
    US
    LLY
    +1.45%
    Unusual Whales·
    US
    LLY
    +1.45%
    Posts
    View More

    In today’s pre-mkt summary for Subscribers: Stocks extended declines as doubts over the credit health of regional US banks drove traders to reduce risk. Gold and bonds were major beneficiaries as in...............

    $Eli Lilly(LLY.US) broke through 723, entering a bull market.

    $Eli Lilly(LLY.US) looks compelling even after rebounding +12% off its lows last week after its Orforglipron weight loss pill showed lower efficacy than expected in Phase 3 trials, sending the stock d...

    ............
    • 0
    • 1
    © 2025 Longbridge｜Disclaimer